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FOCUS EDITORIAL
Plants for human health: greening biotechnology and 
synthetic biology
The concept of growing plants for human health and gen-
eral well-being, rather than for consumption as food alone, 
is changing people’s perception of plant biotechnology 
and synthetic biology. Resurrecting the long-forgotten 
connection between plants and health has launched a 
new generation of botanical therapeutics, which include 
dietary supplements, functional foods, pharmaceuticals 
and multi-component drug mixtures. Technological and 
methodological advances have made the discovery, vali-
dation and manufacture of high-value phytochemicals a 
reality, and botanical therapeutics have come of age.
Plants are integral to human well-being. In addition to their 
obvious nutritional value, for centuries they have also been 
used for their healing properties. Plant parts, potions and 
powders have been, and continue to be, used in traditional 
medicine by a number of  tribes with varying degrees of 
success to boost vigor, as well as to prevent and cure dis-
ease. Archaeological evidence suggests the use of  plants by 
humans for medicinal purposes during the Paleolithic age, 
with the first written evidence dating back to the Sumerians 
(Sumner, 2000).
By the 21st century, the pharmaceutical industry had mostly 
replaced natural plant extracts with chemically synthesized 
molecules to prevent and treat diseases. With the introduction 
of medicine in the form of easy to consume ‘pills’, it is easy to 
dissociate plants from health and thus overlook the many mod-
ern medicines which still contain phytochemicals in their natu-
ral form or as derivatives. Until the 20th century plant extracts 
were regularly screened for novel pharmaceutically active 
compounds, which were then purified from the native plants. 
The emphasis of the pharmaceutical industry then shifted to 
making these natural products synthetically, and using them 
as templates for generating structural analogues as a means of 
obtaining new chemical entities with desired efficacy.
The richness and diversity of novel drugs that can be dis-
covered from plants have also been challenged by competi-
tion from the fields of combinatorial chemistry (Pandeya 
and Thakkar, 2005; Liu et al., 2017) and computational drug 
design (Sliwoski et  al., 2014). It can be argued that several 
years of bioprospecting have resulted in the identification of 
the most relevant and relatively abundant plant natural com-
pounds with pharmaceutical value. However, it is possible 
that several high-value plant-derived compounds with phar-
macological activity still remain undiscovered, either because 
they are produced in plants which are not easily accessible or 
due to a lack of advanced methodologies (Mendelsohn and 
Balick, 1995; Van Wyk, 2015). All living plant species in the 
world together contribute to a greater chemical diversity of 
bioactive compounds than any man-made chemical library, 
and therefore finding novel plant molecules today would 
require more sophisticated discovery approaches.
Engineered well-ness
In addition to the pharmacological relevance of plant natural 
products, there is a growing trend of boosting human well-
ness by incorporating plant parts and products into daily 
diets in the form of functional foods and dietary supplements 
(Box 1). The regular consumption of certain fruits and veg-
etables is suggested to reduce the risk of chronic diseases like 
cancer, diabetes, heart diseases and obesity by functioning as 
medicinal nutrition therapy (Martin et al., 2013). Flavonoids 
comprise one such class of phytochemicals that is commonly 
found in fruits, vegetables and some beverages including wine. 
Flavonoids are polyphenolic compounds with health-pro-
moting biochemical and antioxidant effects that are beneficial 
for nutraceutical, pharmaceutical and cosmetic applications. 
This widely distributed class of plant specialized metabolites 
comprises over 8000 compounds bearing a common diphe-
nylpropane backbone; these are found in several parts of 
the plant and are commonly recognized as flower pigments 
(Panche et al., 2016). It is estimated that the Western popula-
tion consumes 20–50  mg of these compounds in their diet 
daily. Tohge et al. (2017) present an overview of the chemi-
cal diversity of flavonoids across plant species, and showcase 
the impact of technical advancements in making better phy-
tochemical inventories for plants, with a focus on the model 
plant Arabidopsis and the crop plants tomato, maize, rice and 
beans. The increased accessibility of whole-genome sequenc-
ing, together with reverse genetics and molecular phenotyp-
ing, have greatly contributed to the current understanding of 
flavonoid metabolic networks (Tohge et al., 2017). The data 
emerging from the 1001 Arabidopsis genomes project and the 
1000 plants project will enrich the structure-to-function rela-
tionships of flavonoids to benefit translational research in the 
future.
The advent of fast and cost-effective next-generation 
sequencing technologies have revolutionized the study of 
genomics and molecular biology in non-model plants that 
 
© The Author 2017. Published by Oxford University Press on behalf of the Society for Experimental Biology. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which per-
mits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Journal of Experimental Botany, Vol. 68, No. 15 pp. 4009–4011, 2017
doi:10.1093/jxb/erx268 
Downloaded from https://academic.oup.com/jxb/article-abstract/68/15/4009/4108198
by guest
on 05 December 2017
4010 | Editorial
were previously deemed inaccessible. These high-throughput 
platforms enable us to study the unique structural organiza-
tion of genes and the regulatory mechanisms underlying gene 
expression patterns, generate catalogs of specialized metabo-
lism at the species level, and allow evolutionary analysis of 
genes, enzymes and pathways across species (Unamba et al., 
2015). The increased availability of genomic sequencing data 
has also shed light on the phenomenon of gene fusions in the 
biosynthesis of plant natural products. Hagel and Facchini 
(2017) comprehensively describe the gene fusions implicated 
in plant metabolism, discuss the possible mechanisms of their 
origin from an evolutionary perspective, explore the impact 
of fusion events in metabolism, and outline the potential uses 
of gene fusions in biotechnology (Hagel and Facchini, 2017).
The ever-growing technological advances in modern bio-
technology today allow the precise engineering of new traits 
in plants within a short time, as opposed to traditional plant 
breeding. The CRISPR/Cas system allows the engineering 
of plants without residual exogenous DNA, which is ben-
eficial for USDA approval of the final product. Advances 
in technologies and methodologies are revolutionizing plant 
engineering at several levels. Larsen et  al. (2017) present 
interesting new advances in the functional characterization 
of transporters, proteins integral for cellular function. Using 
a combination of in silico, function- and phenotype-driven 
screens, several plant transporters have been identified and 
functionally characterized in different plant species (Larsen 
et  al., 2017). Although transport proteins are not primary 
engineering targets for trait improvement in plants, they offer 
innovative engineering applications for enhancing yield and 
plant performance under stress, both of which are interest-
ing from an agricultural perspective. In fact, next-generation 
sequencing data have enriched our understanding of natural 
genetic diversity among plant membrane transporters, and 
allowed their engineering in crop plants like wheat and rice 
for sustainable food production even under severe environ-
mental conditions (Schroeder et al., 2013).
Today’s companies
Besides trait engineering in plants with a view to augment-
ing human health, the production of high-value phytochemi-
cals using synthetic biology approaches is a reality today. 
Companies like Evolva (evolva.com) and Amyris (amyris.
com) take pride in using synthetic biology strategies for 
solving the supply-chain issue of nature through the bulk 
production of plant natural compounds in microbial organ-
isms. There is an upsurge in biotech startup companies like 
Ginkgo Bioworks (ginkgobioworks.com) that are based on 
engineering microbes for customers across multiple markets. 
Through its foundries, this organism-engineering company 
has scaled and automated the process of making all sorts 
of chemicals in microorganisms. These companies primarily 
focus on metabolically engineering organisms to make profit-
able amounts of high-demand compounds that find applica-
tions in nutrition, health and personal care products, flavors 
and fragrances, and cosmetic additives. Moses et  al. (2017) 
Box 1. Resurrecting the long-forgotten connection between plants and health
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provide a systematic guide for the engineering of biorefiner-
ies from unicellular chassis using rational design principles, 
whilst emphasizing the choice of chassis as a key determinant 
for successful engineering (Moses et al., 2017). It cannot be 
reiterated enough that synthetic biology has simplified and 
made achievable the design and construction of novel bio-
logical systems to screen for and produce new bioactives, food 
additives, fragrances, dietary supplements, and many other 
high-value chemicals.
Future prospects
Plants are poised for a comeback as technological advances 
unravel unique properties and applications for diverse phy-
tochemicals, either as pharmaceuticals or nutraceuticals to 
boost human health (Box 1). High-throughput sequencing 
technologies will generate a torrent of data in the coming 
decade from several ongoing multi-species plant projects. The 
affordability and ever-increasing sensitivity of these tech-
niques has rendered sequencing of non-model, difficult to 
cultivate, and slow-growing plants plausible. Indexing species-
specific phytochemical signatures will enable effective rational 
bioprospecting in the future. Alongside good cataloging of 
phytochemicals, it is also time to expand engineering toolkits 
for both plant biotechnology and synthetic biology to include 
less obvious molecular targets. For instance, the engineering 
of exporters in microorganisms would obviously facilitate the 
export of the product out of the cell, but in addition could 
also circumvent feedback inhibition and compound-asso-
ciated toxicity, which in turn can increase yields and enable 
cost-effective downstream purification of the product.
A big challenge still for phytochemical-based therapeutics 
is integrating the discovery of complex biosynthetic pathways 
with better characterization of molecular targets for the pre-
vention and treatment of complex diseases. Likewise, assess-
ing the compatibility of multifunctional phytochemicals and 
complex multicomponent plant extracts for disease-specific 
treatment is a challenge. However, contemplating the use of 
natural products in functional medicinal foods as a means 
of disease prevention, rather than treatment, is highly con-
ceivable. As holistic approaches to prevention and treatment 
of sickness are increasingly gaining popularity, convincing 
the consumer market to make food choices for health ben-
efits might be easier than currently anticipated. Plants easily 
represent the most abundant renewable source of high-value 
compounds, as they have evolved to synthesize a range of 
complex natural products efficiently. In addition, the upsurge 
in energy and chemical raw material costs, together with envi-
ronmental concerns of carbon dioxide emission are detrimen-
tal to the pharmaceutical manufacturing of plant compounds. 
The result of dramatic advances in metabolic engineering, 
synthetic biology, genomics, proteomics, functional and 
molecular characterization, and pharmaceutical or nutraceu-
tical screening, sets the path forward for botanical therapeu-
tics. In the future, farmers who adapt their farming practices 
for the production of crops that promote health rather than 
provide calories are predicted to profit, and as a result the 
planet could become greener and healthier.
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